October 02, 2014 11:27 AM ET

Pharmaceuticals

Company Overview of Parion Sciences, Inc.

Company Overview

Parion Sciences, Inc., a pharmaceutical company, engages in the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The company primarily focuses on developing therapeutic agents for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disorder, and bronchiectasis. It develops epithelial sodium channel blockers that are used for the treatment of diseases associated with lung, mouth, nose, and the gastrointestinal tract. The company also develops an oral rinse for the relief of chronic dry mouth; and compounds for patients suffering from dry eyes. It was formerly known as CYFI, Inc. and changed its name to Parion Sciences, In...

2800 Meridian Parkway

Suite 195

Durham, NC 27713

United States

Founded in 1999

Phone:

919-313-1180

Fax:

919-313-1190

Key Executives for Parion Sciences, Inc.

Co-Founder
Age: 69
President
Co-Founder and Co-Chairman
Chief Operating Officer
Age: 49
Senior Director of Clinical & Regulatory Operations
Compensation as of Fiscal Year 2014.

Parion Sciences, Inc. Key Developments

Parion Sciences Announces Exclusive Option Agreement for the Development and Commercialization of P-321 in Ophthalmology in Certain Asian Territories

Parion Sciences, Inc. announced that Parion and Santen Pharmaceutical Co. Ltd. have entered into the "OPTION, LICENSE AND DEVELOPMENT AGREEMENT", an exclusive option agreement for the development and commercialization of P-321 for dry eye disease in certain Asian territories. On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease. Parion plans to initiate a Phase 1/2a clinical trial in patients suffering from dry eye disease in July, 2014 in the United States. Under the terms of agreement, Santen will make an undisclosed option payment to secure certain rights to P-321 and to support the upcoming Phase 1/2a clinical trial. Should Santen elect to exercise their option, Santen will have responsibility for all clinical, regulatory, and commercial activity for the ophthalmic use of P-321 in the agreed Asian territories. Parion retains all rights to develop and commercialize P-321 in the rest of the world, including North America and Europe.

Parion Sciences Announces Executive Changes

Parion Sciences announced senior leadership and organizational changes. The changes include the following: Paul Boucher has been promoted to President and will lead the executive management team, business development and provide overall corporate direction. Paul previously served as Vice-President of Finance & Business at Parion. Joe Schachle has been appointed as Chief Operating Officer (COO) and will be responsible for corporate strategy, commercial operations, and corporate operations. Joe joined Parion from Grifols where he served as Head of Global Marketing Operations. Anita Woodring has been appointed as Senior Director of Clinical & Regulatory Operations. Anita is joining Parion from Research Triangle Institute (RTI) where she served as Regulatory Project Leader. These changes are intended to support the growth plans for the organization based on the initiation of trials across 3 clinical programs and increased efforts in early stage research projects.

Parion Sciences Receives FDA Acceptance of the Investigational New Drug Application for Clinical Testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease

Parion Sciences announced that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease. Preclinical data that supported this approval will be presented in a poster session at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on May 6, 2014, in Orlando, Fla. P-321 is the result of a comprehensive research effort to develop a potent ENaC inhibitor with unique pharmacokinetic and pharmacodynamics characteristics designed for topical ocular administration, metabolic stability and limited systemic exposure. Parion Sciences has completed all the preclinical safety and mechanistic studies required to initiate clinical studies in humans.

Similar Private Companies By Industry

Company Name Region
Forgiven Bottling Group, Inc. United States
Erimos Pharmaceuticals, LLC United States
Scios, Inc. United States
Southwood Pharmaceuticals, Inc. United States
FemmePharma Global Healthcare, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Parion Sciences, Inc., please visit www.parion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.